CompletedPhase 1NCT00008177
Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Studying Acquired idiopathic sideroblastic anemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fred Hutchinson Cancer Center
- Principal Investigator
- Johnnie OrozcoFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
- Intervention
- iodine I 131 monoclonal antibody BC8(radiation)
- Enrollment
- 79 enrolled
- Eligibility
- 50 years · All sexes
- Timeline
- 1999 – 2010
Study locations (1)
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00008177 on ClinicalTrials.govOther trials for Acquired idiopathic sideroblastic anemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06270771OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot StudySunnybrook Health Sciences Centre
- RECRUITINGNANCT04869683Biocollection in MyeloDysplastic Syndrome (P-MDS)University Hospital, Brest
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT00392353Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaNational Cancer Institute (NCI)
See all trials for Acquired idiopathic sideroblastic anemia →